文献速递白血病造血干细胞移植与细胞治疗

儿童急性淋巴细胞白血病allo-HSCT中白消安或曲奥舒凡预处理后的结局相当:FORUM研究结果

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.
PubMed 文献 · Blood Adv · 2025-01-01

FORUM研究预设比较了2013至2018年接受allo-HSCT的儿童ALL患者中BU/THIO/FLU与TREO/THIO/FLU预处理的结局,分别纳入180例和128例。两组3年总生存、无事件生存、累积复发率、非复发死亡及GVHD均相当,各有1例致死性肝静脉闭塞病。作者结论认为对>4岁且存在TBI禁忌或无法获得TBI的患者,这两种方案可作为TBI的替代。

要点

  • BU组3年总生存0.71 vs TREO组0.72,3年无事件生存BU组0.60 vs TREO组0.55。
  • 3年累积复发率BU组0.31 vs TREO组0.36,非复发死亡BU组0.08 vs TREO组0.09,两组相当。
  • 两组急慢性GVHD及3年无GVHD无复发生存无显著差异,各有1例致死性肝静脉闭塞病。

核心结论

  • BU/THIO/FLU或TREO/THIO/FLU方案可作为>4岁且存在TBI禁忌或无法获得TBI的ALL患者的替代选择。

研究设计与样本

  • 国际、前瞻性3期FORUM研究预设比较,随机纳入417例4-18岁完全缓解期接受HLA相合同胞或无关供者allo-HSCT的ALL患者。
  • 本报告分析2013至2018年接受BU/THIO/FLU(180例)或TREO/THIO/FLU(128例)预处理的患者,数据截至2023年2月,中位随访4.2年(范围0.3-9.1)。
  • 试验注册号NCT01949129。

主要发现

  • 3年总生存BU组0.71(95%CI 0.64-0.77)vs TREO组0.72(95%CI 0.63-0.79)。
  • 3年无事件生存BU组0.60(95%CI 0.53-0.67)vs TREO组0.55(95%CI 0.46-0.63)。
  • 3年累积复发率BU组0.31(95%CI 0.25-0.38)vs TREO组0.36(95%CI 0.27-0.44)。
  • 3年非复发死亡BU组0.08(95%CI 0.05-0.13)vs TREO组0.09(95%CI 0.05-0.15)。
  • 3年无GVHD无复发生存BU组0.48(95%CI 0.41-0.55)vs TREO组0.45(95%CI 0.37-0.54)。

临床怎么用

  • 作者结论认为BU/THIO/FLU或TREO/THIO/FLU方案可作为>4岁且存在TBI禁忌或无法获得TBI的ALL患者的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The superiority of total body irradiation (TBI)-based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international, prospective phase-3 FORUM study, randomizing 417 patients aged 4-18 years in complete remission (CR), who received allo-HSCT from HLA-matched sibling or unrelated donors. Because of the unavailability of TBI in some regions and to accommodate individual contraindications, this study reports the prespecified comparison of outcomes of patients receiving busulfan (BU)- or treosulfan (TREO)-based regimens from 2013 to 2018. Overall, 180 and 128 patients received BU/thiotepa (THIO)/fludarabine (FLU) or TREO/THIO/FLU, respectively. Data were analyzed as of February 2023, with a median follow-up of 4.2 years (range, 0.3-9.1). 3-year overall survival was 0.71 (BU, 95% confidence interval [0.64-0.77]) and 0.72 (TREO, [0.63-0.79]) and 3-year event-free survival was 0.60 (BU, [0.53-0.67]) and 0.55 (TREO, [0.46-0.63]). The 3-year cumulative incidence of relapse (BU, 0.31 [0.25-0.38]; TREO, 0.36 [0.27-0.44]); and nonrelapse mortality (BU, 0.08 [0.05-0.13]; TREO, 0.09 [0.05-0.15]) were comparable. One case of fatal veno-occlusive disease occurred in each group. No significant differences in acute and chronic graft-versus-host disease (GVHD) or 3-year GVHD-free and relapse-free survival (BU, 0.48 [0.41-0.55]; TREO, 0.45 [0.37-0.54]) were recorded. Outcomes for patients in first and second CR were similar irrespective of the regimen. In conclusion, BU/THIO/FLU or TREO/THIO/FLU regimens can be an alternative to TBI for patients with ALL aged >4 years with contraindications or lack of access to TBI. This trial was registered at www.ClinicalTrials.gov as #NCT01949129.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kalwak K, Moser LM, Pötschger U, et al. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. Blood Adv. 2025. PMID: 39602342. doi:10.1182/bloodadvances.2024014548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。